JP Patent

JP7179049B2 — オレキシン受容体拮抗薬の結晶形及びその製造方法並びに用途

Assigned to Bergen Pharmaceutical LLC · Expires 2022-11-28 · 3y expired

What this patent protects

Patent listed against Dayvigo.

Drugs covered by this patent

Patent Metadata

Patent number
JP7179049B2
Jurisdiction
JP
Classification
—
Expires
2022-11-28
Drug substance claim
No
Drug product claim
No
Assignee
Bergen Pharmaceutical LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.